Gaorong Capital partner: AI drug discovery still at 0-to-1 stage, bet on long boards
创业邦 · wechat · 2026-11-21
Gaorong Capital managing director Le Beilin shared his biotech investment playbook at DEMOCHINA 2026, drawing on cases like Protoby (acquired by Genmab for $1.8B) and Cotounsel (7B?) — actually a $700M strategic partnership with Medtronic.
Key points:
- AI drug discovery remains at the 0-to-1 stage, mostly early R&D; he joined ByteDance's internal AI small-molecule platform and argues AI-pharma valuations ($10B level) have huge headroom vs trillion-dollar LLM companies.
- Brain-computer interfaces are a systematic focus: investments include China's Qidi Medical and Harvard-spinout Axoft.
- SiRNA bets are expanding from liver-targeting to extra-hepatic delivery.
On the BD licensing wave, he sees value but warns against one-off "fire sales" that drain China's innovative assets. Companies that survive cycles share continuous team learning, strong cash reserves (70-80% of failed deals died from cash problems), and openness to talent.
More from Companies & People
- Analysts Say Jensen Huang Could Launch Full Proxy Fight for Nvidia Board Comeback — beffjezos · 2026-11-22
- NVIDIA veteran hopes probes clear Jensen Huang: 'What he created can't be destroyed easily' — JFPuget · 2026-11-22
- Blogger publicly asks OpenAI why GPT-6.2 Sol and Astra perform so poorly — kimmonismus · 2026-11-22
- Not wrappers: over 50% of RL env companies started with ambitious original ideas — himanshustwts · 2026-11-22
- Blogger zetalyrae goes full-time AI writer on 6-month BlueDot Impact grant — zetalyrae · 2026-11-22
- Faculty sending their PhD grads to industry, in one meme — docmilanfar · 2026-11-22